In addition to Aranesp, Amgen currently has three other new products that should invigorate Amgen for 2001-2002. The rheumatoid arthritis treatment Anakinra, waiting to hit the market, Abarelix-Depot will likely receive FDA approved for treating prostate cancer, and SD01, the sustained duration Neupogen are several near term drivers for Amgen's growth. Currently, the stock is trading in the mid-50s. And with the retreat in its share price, it will create a buying opportunity with more upside potential for shareholders. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.